Cargando…

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs

INTRODUCTION: Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes a considerable burden for the patient and society. It is not clear yet whether aiming for remission (REM) is worthwhile, especially when compared with low disease activity (LDA). METHODS: In 356 consecutive RA pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radner, Helga, Smolen, Josef S, Aletaha, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979137/ https://www.ncbi.nlm.nih.gov/pubmed/24555808 http://dx.doi.org/10.1186/ar4491

Ejemplares similares

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
por: Radner, Helga, et al.
Publicado: (2015)

Value of self-performed joint counts in rheumatoid arthritis patients near remission
por: Radner, Helga, et al.
Publicado: (2012)

Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
por: Smolen, Josef S., et al.
Publicado: (2017)

Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
por: Kapral, Theresa, et al.
Publicado: (2007)

Developments in the clinical understanding of rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2009)

American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
por: Studenic, Paul, et al.
Publicado: (2023)

American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision
por: Studenic, Paul, et al.
Publicado: (2022)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
por: Aletaha, Daniel, et al.
Publicado: (2015)

Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis
por: Gärtner, M, et al.
Publicado: (2016)

Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
por: Schoels, M., et al.
Publicado: (2017)

The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2022)

Viewpoint: how to measure comorbidities in patients with rheumatoid arthritis – clinical and academic value
por: Radner, Helga
Publicado: (2023)

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
por: Smolen, Josef S, et al.
Publicado: (2008)

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction
por: Smolen, Josef S, et al.
Publicado: (2011)

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
por: Smolen, Josef S., et al.
Publicado: (2018)

Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns
por: Platzer, Alexander, et al.
Publicado: (2019)

Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure
por: Kapral, Theresa, et al.
Publicado: (2006)

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2019)

Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis
por: Mandl, Peter, et al.
Publicado: (2020)

Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
por: Lopez-Romero, Pedro, et al.
Publicado: (2022)

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
por: Aletaha, Daniel, et al.
Publicado: (2005)

Remission in Rheumatoid Arthritis
por: Shammas, Rania M., et al.
Publicado: (2010)

Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials
por: Smolen, Josef, et al.
Publicado: (2019)

The science of rheumatoid arthritis: a prelude
por: Smolen, Josef S
Publicado: (2005)

Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents
por: Gülfe, Anders, et al.
Publicado: (2009)

Reexamining Remission Definitions in Rheumatoid Arthritis: Considering Disease Activity Score in 28 Joints, C‐Reactive Protein, and Patient Global Assessment
por: Felson, David T., et al.
Publicado: (2021)

Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis
por: Borst, Carina, et al.
Publicado: (2021)

Autoantibodies in rheumatoid arthritis and their clinical significance
por: Steiner, Günter, et al.
Publicado: (2002)

Ultrasound remission in patients with rheumatoid arthritis in clinical remission
por: Fakhfakh, Rym, et al.
Publicado: (2021)

Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis
por: Studenic, Paul, et al.
Publicado: (2021)

Therapeutic implications of autoantibodies in rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2016)

Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight–joint Disease Activity Score, C-reactive protein level and patient global assessment
por: Felson, David, et al.
Publicado: (2021)

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor
por: Tan, Eng M., et al.
Publicado: (2016)

Patient’s perspective of sustained remission in rheumatoid arthritis
por: Contreras-Yáñez, Irazú, et al.
Publicado: (2017)

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE)
por: Smolen, Josef S., et al.
Publicado: (2015)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
por: Rahman, Mahboob U, et al.
Publicado: (2011)

Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?
por: Aletaha, Daniel
Publicado: (2006)

Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission
por: Ben Abdelghani, Kawther, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v3fqi6mkuqkbntgd9nskv470rh